ArticleFrontiers in oncology2025
Atrial arrhythmias associated with anti-tumor drugs in patients with malignant tumors and type 2 diabetes mellitus.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Patients with malignancies and type 2 diabetes mellitus (T2DM) face heightened risks of cardiotoxicity from antitumor therapies, yet the interplay between diabetes, antitumor drugs, and atrial arrhythmias remains underexplored. This study investigates the incidence and risk factors of atrial arrhythmias in this high-risk population. Methods: In this retrospective cohort study, 171 patients with T2DM and malignancies receiving antitumor therapy at Zhejiang Hospital (January 2022-January 2024) were analyzed. Serial 12-lead electrocardiograms (ECGs) were performed pre- and post-chemotherapy cycles to detect new-onset atrial arrhythmias. Multivariate Cox regression identified risk factors, adjusting for age, hypertension, renal function, and cardiac biomarkers (troponin I, NT-proBNP). Subgroup analyses stratified by tumor type, diabetes duration, and drug class were conducted. Results: Atrial arrhythmias occurred in 10.5% of patients (18/171), with a significantly higher incidence in diabetics versus non-diabetics (18.4% vs. 4.2%, P=0.004). Advanced age (HR=10.25, 95% CI 1.01-104.56; P=0.049) and anthracycline use (HR=2.70, 95% CI 1.02-7.19; P=0.045) independently predicted arrhythmia risk. Diabetes duration ≥5 years (HR=2.85, 95% CI 1.22-6.70; P=0.016) and reduced eGFR (<60 mL/min/1.73m²; HR=2.58, 95% CI 1.04-6.39; P=0.039) further elevated risk. A synergistic interaction was observed between diabetes and anthracyclines (HR=3.95, 95% CI 1.58-9.85; P=0.002). Dynamic rises in NT-proBNP (≥50%) and troponin I (≥5 ng/L) emerged as strong predictors (HR=2.11 and 2.73, respectively; P<0.05). Conclusion: T2DM significantly amplifies atrial arrhythmia risk in cancer patients receiving antitumor drugs, particularly anthracyclines. Age, ischemic heart disease, and biomarker trends are critical risk indicators. Proactive ECG and biomarker monitoring, coupled with cardio-oncology collaboration, are essential for mitigating arrhythmia-related morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.